Stockscreener 앱 받기
0.99
4.49%
0.0425
전일 마감가:
$0.9475
열려 있는:
$0.86
하루 거래량:
165.46K
Relative Volume:
1.08
시가총액:
$23.00M
수익:
-
순이익/손실:
$-13.76M
주가수익비율:
-1.0645
EPS:
-0.93
순현금흐름:
-
1주 성능:
-0.50%
1개월 성능:
-10.00%
6개월 성능:
-21.43%
1년 성능:
-51.94%
1일 변동 폭
$0.85
$1.04
1주일 범위
$0.85
$1.04
52주 변동 폭
$0.512
$2.248
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
NRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.99 | 23.00M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN
Breakthrough ALS Treatment Shows Disease-Modifying Results in Phase 2b Trial - Stock Titan
Lou Gehrig's Disease Pipeline: 75+ Innovators Pioneering Breakthrough Therapies | DelveInsight - openPR.com
NeuroSense Updates on Pharmaceutical Partnership Discussions - TipRanks
Amyotrophic Lateral Sclerosis Pipeline: Advancing the Future with 50+ Innovators Leading Breakthrough Therapies - openPR.com
Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth - Business Wire
NeuroSense Therapeutics (NRSN) to Release Earnings on Monday - Defense World
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug - Business Wire
NeuroSense Advances PrimeC Commercialization in Canada - TipRanks
PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape - Marketscreener.com
Breakthrough: NeuroSense ALS Treatment Cuts Disease Progression by 36%, Boosts Survival 43% - StockTitan
The next rare disease roadblock: American innovation moving ex-U.S. - BioCentury
NeuroSense Therapeutics Reports Positive Phase 2b Study Results for ALS Treatment - TipRanks
NeuroSense Therapeutics Reports Key Progress and Financials - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Trading Down 0.4% – Here’s What Happened - Defense World
NeuroSense regains Nasdaq compliance with equity boost - Investing.com
NeuroSense regains Nasdaq compliance with equity boost By Investing.com - Investing.com Nigeria
NeuroSense Regains Nasdaq Compliance, Strengthens Position for ALS Treatment - TipRanks
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - StreetInsider.com
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule - GuruFocus.com
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit - GuruFocus.com
NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In R - GuruFocus.com
Neurosense Therapeutics Ltd (NRSN-Q) QuotePress Release - The Globe and Mail
Analyzing NeuroSense Therapeutics (NASDAQ:NRSN) & Avidity Biosciences (NASDAQ:RNA) - Defense World
NeuroSense Partners with Pharma Giant to Propel ALS Drug PrimeC - TipRanks
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS - Nasdaq
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Shares Bought by XTX Topco Ltd - Defense World
NeuroSense Signs Binding Term Sheet With Global Pharma To Advance PrimeC For ALS Treatment - Nasdaq
NeuroSense Advances ALS Treatment with PrimeC, Boosts Financial Position - TipRanks
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results - citybiz
NeuroSense's ALS Drug Shows Breakthrough Results: 58% Better Survival Rate in Phase 2b Trial - StockTitan
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire) - Aktiellt
NeuroSense Therapeutics Regains Nasdaq Compliance - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Receives “Hold” Rating from Maxim Group - Defense World
Maxim cuts NeuroSense shares rating to hold on capital concerns By Investing.com - Investing.com South Africa
Maxim cuts NeuroSense shares rating to hold on capital concerns - Investing.com
Comparing Emmaus Life Sciences (OTCMKTS:EMMA) & NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World
NeuroSense aligns with FDA on Phase 3 ALS drug study By Investing.com - Investing.com Australia
NeuroSense Receives FDA Approval for Phase 3 Study of ALS Treatment - TipRanks
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Desig - GuruFocus.com
NeuroSense aligns with FDA on Phase 3 ALS drug study - Investing.com
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC - Marketscreener.com
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC (PR Newswire) - Aktiellt
Neurosense Therapeutics Ltd (NRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):